The relevance of information generated byin vitroexperimental models to clinical doxorubicin cardiotoxicity

A clinicopathologic analysis of adriamycin cardiotoxicity

1973 • 1,534 citations

Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood

1991 • 1,386 citations

Adriamycin

1974 • 1,051 citations

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01

2001 • 853 citations

Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion

1982 • 768 citations

Female Sex and Higher Drug Dose as Risk Factors for Late Cardiotoxic Effects of Doxorubicin Therapy for Childhood Cancer

1995 • 766 citations

Chronic Progressive Cardiac Dysfunction Years After Doxorubicin Therapy for Childhood Acute Lymphoblastic Leukemia

2005 • 675 citations

The Effect of Dexrazoxane on Myocardial Injury in Doxorubicin-Treated Children with Acute Lymphoblastic Leukemia

2004 • 614 citations

Doxorubicin Administration by Continuous Infusion Is Not Cardioprotective: The Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol

2002 • 177 citations

Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats

2000 • 115 citations

Does anthracycline administration by infusion in children affect late cardiotoxicity?

2004 • 84 citations

Cardiac matrix alterations induced by adriamycin.

1988 • 49 citations

Doxorubicin cardiotoxicity in children: Comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration

1998 • 48 citations

Maturation of Responsiveness to Cardioactive Drugs

1973 • 45 citations

Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules

2001 • 41 citations

Emergence of beta-adrenergic sensitivity in the developing chicken heart.

1981 • 20 citations

A precise pharmacodynamic study showing the advantage of a marked reduction in cardiotoxicity in continuous infusion of doxorubicin

2006 • 9 citations